2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2459

Effect of Obesity and Surgical Weight Loss on Joint Surgery Hospitalizations in Psoriatic Arthritis: Data from National Inpatient Sample
Abstract Number: 2460

Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Abstract Number: 2461

Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement
Abstract Number: 2462

Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort
Abstract Number: 2463

Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Abstract Number: 2464

Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results
Abstract Number: 2465

Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis
Abstract Number: 2466

Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients
Abstract Number: 2467

Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries
Abstract Number: 2468

JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target
Abstract Number: 2469

Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance
Abstract Number: 2470

Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis
Abstract Number: 2471

Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study
Abstract Number: 2472

The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis
Abstract Number: 2473

Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].